

Datasheet for ABIN1693571

anti-HMG20B antibody (AA 1-100) (AbBy Fluor® 350)



Go to Product page

()	ve	r\/i	۱۸/
\cup	V C	1 / 1	 v v

Quantity:	100 μL
Target:	HMG20B
Binding Specificity:	AA 1-100
Reactivity:	Mouse
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This HMG20B antibody is conjugated to AbBy Fluor® 350
Application:	Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))
Product Details	

Immunogen:	KLH conjugated synthetic peptide derived from human BRAF35
Isotype:	IgG
Cross-Reactivity:	Mouse
Predicted Reactivity:	Human,Rat,Cow
Purification:	Purified by Protein A.

Target Details

Target:	HMG20B
Alternative Name:	BRAF35 (HMG20B Products)

Target Details

Background:

Synonyms: BRAF25, BRAF35, BRCA 2 Associated Factor 35 kDa, BRCA2 associated factor 35, BRCA2-associated factor 35, High Mobility Group Protein 20B, HM20B_HUMAN, HMG 20B, HMG box containing protein 20B, HMG box-containing protein 20B, HMG domain-containing protein 2, HMG domain-containing protein HMGX2, hmg20b, HMGX2, PP7706, pp8857, SMARCE1 related protein, SMARCE1-related protein, SMARCE1r, sox like, Sox like transcriptional factor, Sox-like transcriptional factor, SOXL, Structural DNA binding protein BRAF35, Structural DNA-binding protein BRAF35, SWI/SNF related, SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily E member 1 related, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related

Background: The breast cancer susceptibility gene (BRCA1) localizes to chromosome 17q. Mutations within this gene account for approximately 45% of families with high incidence of breast cancer and at least 80% of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2, located on chromosome 13q12-13, also confers a high incidence of breast cancer, but unlike BRCA1, BRCA2 does not confer a substantially elevated risk of ovarian cancer. The BRCA2-Associated Factor 35 (BRAF35) protein forms a complex with BRCA2, which associates with condensed chromatin during histone H3 phosphorylation. BRAF35 expression levels are highest in proliferating tissues and parallel BRCA2 expression patterns. The structure of BRAF35 includes a kinesin-like coiled coil domain and a nonspecific DNA binding HMG domain. The chromatin localization of BRAF35 and antibody microinjection studies indicate a role for the BRAF35/BRCA2 complex in cell cycle regulation.

Gene ID:

10362

Application Details

Application Notes:

IF(IHC-P) 1:50-200

IF(IHC-F) 1:50-200

IF(ICC) 1:50-200

Restrictions:

For Research Use only

Handling

Format:

Liquid

Concentration:

1 μg/μL

Handling

Buffer:	Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
Preservative:	ProClin
Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
Storage:	-20 °C
Storage Comment:	Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Expiry Date:	12 months